Prolonged administration of low-molecular heparins in the prophylaxis of postoperative thrombosis

Česká verzia

Authors: M. Čepelák
Authors place of work: I. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Karel Opatrný jr., DrSc.
Published in the journal: Vnitř Lék 2005; 51(5): 555-559
Category: Reviews

Summary

Low-molecular-heparins have become a standard medication of venous thrombosis prevention in orthopaedic and general surgery. Reasons for extended prophylaxis with low–molecular heparins after hospital discharge are best evident in patients with total hip replacement. In this patient group a high incidence of thromboembolic complications in the late period after surgery has been ascertained and the origin of new asymptomatic thrombosis cases has been documented by phlebography and duplex sonography. A prolonged treatment with low–molecular heparins leads to a significant lowering of the frequency of manifest as well as asymptomatic thrombosis and finds application in other indications of thrombosis prophylaxis as well.

Key words:
low-molecular heparins – preventionpostoperative thrombosis – total hip replacement – thromboembolic complications

Zdroje

1. Arnold MD, Kahn RS, Shrier I. Missed opportunities for prevention of venous thromboembolism. An evaluation of the use of thromboprophylaxis guidelines. Chest 2001; 120: 1964–1971.

2. Bergqvist D, Agnelli G, Cohen TA et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346(13): 975–979.

3. Bergqvist D, Lowe G. Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts. Arch Intern Med 2002; 162: 2173–2176.

4. Clagett GP, Anderson FA, Geerts WH et al. Prevention of venous thromboembolism. Chest 1998; 114: 531S–560S.

5. Dahl OE, Andreassen G, Aspelin T. Prolonged thromboprophylaxis following hip replacement surgery – results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin. Thromb Haemost 1997; 77: 26–31.

6. Dulíček P, Pavlata J, Karpaš K et al. Profylaxe tromboembolické nemoci po náhradě kyčelního kloubu. Acta Chir Orthop Traumatol Čechosl 2000; 67: 243–245.

7. Eriksson IB. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res 2003; 109: S23–S29.

8. Eriksson IB, Bergqvist D, Kalebo I et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441–1447.

9. Eriksson IB, Lassen RM. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Arch Intern Med 2003; 163: 1337–1342.

10. Eriksson IB, Orgren M, Eriksson GU et al. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thromb Res 2002; 105: 371–378.

11. Francis WC, Berkowitz DS, Comp CP. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349(18): 1703–1712.

12. Francis WC, Davidson LB, Berkowitz DS. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 2002; 137: 648–655.

13. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119(Suppl 1): 132S–175S.

14. Haentjens P. Venous thromboembolism after total hip arthroplasty a review of incidence and prevention during hospitalization and after hospital discharge. Acta Orthop Belg 2000; 66(1): 1–8.

15. Haentjens P, Delincé PH. Prevention of venous thromboembolism after hospital discharge. Hip International 2001; 11(1): 25–36.

16. Howard WA, Aaron DS. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. Thromb Haemost 1998; 79: 902–906.

17. Hull DR, Pineo FG, Stein DP et al. Extended out–of–hospital low–molecular– weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review. Ann Intern Med 2001; 135: 858–869.

18. Jorgensen SP, Warming T, Hansen K et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast A venografic controlled study. Thromb Res 2002; 105: 477–480.

19. Koopman MMW, Büller HR. Short–and long–acting pentasaccharides. J Intern Med 2003; 254: 335–342.

20. Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. Hamostasis 1993; 23(Suppl 1): 20–26.

21. Lassen RM, Bauer AK, Eriksson IB et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double–blind comparison. Lancet 2002; 359: 1715–1720.

22. Lee AYY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.

23. Menzin J, Colditz AG, Regan MM et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757–764.

24. Nicolaides AN, Bergqvist D, Hull R. Prevention of venous thromboembolism. International consensus statement (Guideline according to scientific evidence). Internat Angiol 1997; 16(1): 3–38.

25. PERSIST investigators: A novel long-acting synthetic factor Xa inhibitor (SanOrg 34006) to replace warfarin for secondary prevention in venous thrombosis. A phase II evaluation. J Thromb Haemost 2003; 2(1): 47–53.

26. Planes A, Vochelle N, Darmon JY et al. Efficacy and safety of post-discharge administration of enoxaparin in the prevention of venous thrombosis after total hip replacement. A prospective randomised double-blind placebo–controlled trial. Lancet 1996; 348: 224–228.

27. Roth P. Thromboembolieprophylaxe bei ambulant duchgefuhrten arthroskopischen Meniskusoperationen. Orthop Praxis 1995; 5: 345–348.

28. Samama MC, Vray M, Barré J et al. Extended venous thromboembolism prophylaxis after total hip replacement. Arch Intern Med 2002; 162: 2191–2196.

29. Schulman S. Unresolved issues in anticoagulant therapy. J Thromb Haemost 2003; 1: 1464–1470.

30. Schulman S, Wahlander K, Lundstrom T et al. Secondary prevention of thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713–1721.

31. Spannagel U, Kujath P. Low molecular weight heparin for the prevention of thromboembolism in outpatients immobilized by plaster cast. Semin Thromb Hemost 1993; 19(1): 131–141.

32. Štědrý V. Totální endoprotéza kyčelního kloubu. Doporučený postup ČLS JEP reg. č. A/113/206 2002; 1–8 (www.cls.cz/dp/index.html).

33. Turpie GGA, Bauer AK, Eriksson IB et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch Intern Med 2002; 162: 1833–1840.

34. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: 1–4.

35. White RH, Romano PS, Zhou H et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158(14): 1525–1531.

36. Zeman J, Dungl P, Fajtová A et al. Zjišťování rizika trombózy dolních končetin po implantaci endoprotézy kyčelního kloubu ve fázi rehabilitace po propuštění z nemocnice. Prakt Flebol 1999; 1: 20–26.